In the past week, QLGN stock has gone down by -19.42%, with a monthly decline of -16.42% and a quarterly plunge of -37.68%. The volatility ratio for the week is 6.68%, and the volatility levels for the last 30 days are 6.76% for Qualigen Therapeutics Inc The simple moving average for the past 20 days is -19.01% for QLGN’s stock, with a -63.09% simple moving average for the past 200 days.
Is It Worth Investing in Qualigen Therapeutics Inc (NASDAQ: QLGN) Right Now?
QLGN has 36-month beta value of -0.67. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QLGN is 0.69M, and currently, short sellers hold a 10.07% ratio of that float. The average trading volume of QLGN on January 28, 2025 was 59.93K shares.
QLGN) stock’s latest price update
The stock of Qualigen Therapeutics Inc (NASDAQ: QLGN) has decreased by -15.16 when compared to last closing price of 3.97.Despite this, the company has seen a loss of -19.42% in its stock price over the last five trading days. globenewswire.com reported 2024-11-25 that New York, Nov. 25, 2024 (GLOBE NEWSWIRE) — Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations.
QLGN Trading at -19.89% from the 50-Day Moving Average
After a stumble in the market that brought QLGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.56% of loss for the given period.
Volatility was left at 6.76%, however, over the last 30 days, the volatility rate increased by 6.68%, as shares sank -21.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.22% lower at present.
During the last 5 trading sessions, QLGN fell by -19.35%, which changed the moving average for the period of 200-days by -82.26% in comparison to the 20-day moving average, which settled at $4.16. In addition, Qualigen Therapeutics Inc saw -19.99% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for QLGN
The total capital return value is set at 3.13. Equity return is now at value -1656.23, with -234.45 for asset returns.
Based on Qualigen Therapeutics Inc (QLGN), the company’s capital structure generated -2.03 points at debt to capital in total, while cash flow to debt ratio is standing at -6.78. The debt to equity ratio resting at -0.67. The interest coverage ratio of the stock is -6.41.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.52.
Conclusion
To put it simply, Qualigen Therapeutics Inc (QLGN) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
